AR100327A1 - Inhibidores de quinasa relacionados con tropomiosina - Google Patents
Inhibidores de quinasa relacionados con tropomiosinaInfo
- Publication number
- AR100327A1 AR100327A1 ARP150101378A ARP150101378A AR100327A1 AR 100327 A1 AR100327 A1 AR 100327A1 AR P150101378 A ARP150101378 A AR P150101378A AR P150101378 A ARP150101378 A AR P150101378A AR 100327 A1 AR100327 A1 AR 100327A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- het
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o uno de sus profármacos o una de sus sales farmacéuticamente aceptables, en donde R¹ es CN, CO₂Rˣ, CO-(NHet), CONRˣ¹-(cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹(CRˣRʸ)ₘ(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹(CRYRX)ₘCO(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹(CRYRX)ₘNRˣ¹CO(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹CO(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹CO-(CRˣRʸ)ₘ(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²), CONRˣ¹(CRˣRʸ)ₘCONRˣ¹-(NHet, NRˣ¹Rˣ², cicloalquilo C₃₋₈, Ar, Het o Rˣ²); Rˣ¹ y Rˣ² son cada uno, de modo independiente, H, alquilo C₁₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, OH, NH₂, NH(alquilo C₁₋₆), N(alquilo C₁₋₆)₂, CN, (alcoxi C₁₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, OH, NH₂, NH(alquilo CN, opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, OH, NH₂), N(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, OH, NH₂)₂ y alcoxi C₁₋₆) y alcoxi C₁₋₆) y (alquilo C₁₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, NH₂, NH(alquilo C₁₋₆), N(alquilo C₁₋₆)₂ y alcoxi C₁₋₆), o, junto con el átomo de nitrógeno al que están unidos, Rˣ¹ y Rˣ² forman un anillo NHet; NHet es un anillo heterocíclico saturado o insaturado de 4 a 8 miembros con un átomo de N del anillo directamente ligado con el resto ligado, que tiene de 0 a 2 otros heteroátomos del anillo seleccionados, de modo independiente, de N, O y S; Het es un anillo heterocíclico saturado o insaturado de 4 a 8 miembros que tiene al menos 1 y hasta 3 heteroátomos del anillo seleccionados, de modo independiente, de N, O y S; los grupos cicloalquilo C₃₋₈, NHet y Het pueden ser monocíclicos, bicíclicos, en puente o espirocíclicos si lo permite la cantidad de átomos del anillo; Ar es fenilo, en donde cada uno de cicloalquilo C₃₋₈, Ar, NHet y Het están opcionalmente sustituidos, donde lo permita la valencia, con hasta 5 sustituyentes seleccionados, de modo independiente, de alquilo C₁₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, OH, CN, NRˣ¹Rˣ², NHCORˣ¹, NHCO(CRˣRʸ)ₘNRˣ¹Rˣ², CONRˣ¹Rˣ², alcoxi C₁₋₆, alcoxi C₁₋₆-C(O)-, CONRˣ¹Rˣ², alquil C₁₋₆-tio, hidroxi-alquilo C₁₋₆, alquil C₁₋₆-SO₂-, CO₂Rˣ y alcoxi C₁₋₃-alquil C₁₋₃-O-C(O)-; halógeno, CN, alcoxi C₁₋₆, alcoxi C₁₋₆-C(O)-, CONRˣ¹Rˣ², alquil C₁₋₆-tio, hidroxi-alquilo C₁₋₆, alquil C₁₋₆-SO₂-, CO₂Rˣ, alcoxi C₁₋₃-alquil C₁₋₃-O-C(O)-, OH, =O, O(alquilo C₁₋₆ opcionalmente sustituido con uno o varios F), C(O)(alquilo C₁₋₆ opcionalmente sustituido con uno o varios F), alquilo C₁₋₆, opcionalmente sustituido con uno o varios F, alquilo C₁₋₆ sustituido con CN, alquilo C₁₋₆, sustituido con hasta 3 OH, alquilo C₁₋₆ sustituido con CO₂(alquilo C₁₋₄), alquilo C₁₋₆ sustituido con uno o varios alcoxi C₁₋₃, SO₂(alquilo C₁₋₆ opcionalmente sustituido con uno o varios F), CO₂(alquilo C₁₋₆), cicloalquilo C₃₋₆, C₍O₎₍ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₆), N(H o alquil C₁₋₃)CO(alquilo C₁₋₃) y N(H o alquil C₁₋₃)(H o alquilo C₁₋₃); m es un número entero de 1 a 4; R²ᵃ, R²ᵇ, R²ᶜ, R²ᵈ y R²ᵉ se seleccionan cada uno, de modo independiente, de H, OH, halógeno, NH₂ o metilo opcionalmente sustituido con hasta 3 F; X¹, X², R¹ᵃ, R⁴, R⁴ᵃ y R⁵ se seleccionan cada uno, de modo independiente, de H, cicloalquilo C₃₋₆, alquilo C₀₋₆ opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de halógeno, CN, CO₂H, OH, (alcoxi C₁₋₆ opcionalmente sustituido con hasta 3 F), S(O)ₚ(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 F), C(O)(alcoxi C₁₋₆ opcionalmente sustituido con hasta 3 F o con alcoxi C₁₋₃), C(O)NRˣ¹Rˣ², NRˣ¹Rˣ², O(cicloalquilo C₃₋₆), Ar, Het, CO₂(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 F), NRˣ¹C(O)(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 F), NRˣ¹C(O)NRˣ²(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 F), OC(O)(alquilo C₁₋₆ opcionalmente sustituido con hasta 3 F) y OC(O)NRˣ¹Rˣ²; p es 0, 1 ó 2; R³ es H, alquilo C₀₋₃ opcionalmente sustituido con CN, N(H o alquilo C₁₋₃ opcionalmente sustituido con uno o varios F)(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F), Het, OH, SH, Ar, OAr, uno o varios halógenos, CONRXRY, CO₂CRXRY, CONRXRY, S(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F), S-(CRXRY)₀₋₂Het, S-(CRXRY)₀₋₂Ar, S-(CRXRY)₀₋₂(cicloalquilo C₃₋₆), SONRXRY, SO₂CRXRY, O(CRXRY)ₘ(CO)NRXRY, NHSO₂(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F o con Ar o Het o (cicloalquilo C₃₋₆)), NHSO₂NRXRY, CONHSO₂CRXRY, alquino C₂₋₆, alqueno C₂₋₆, cicloalquilo C₃₋₆ opcionalmente sustituido con uno o varios F o con O(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F), o R³ es NH(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F), NH(cicloalquilo C₃₋₆), NH-Het, NHCO(alquilo C₁₋₄ opcionalmente sustituido con uno o varios F), NHCOCRˣRʸHet, NHCOCRˣRʸAr, NHSO₂-(alquilo C₁₋₆), NHCONH-(H o alquilo C₁₋₆), NHCONH-(cicloalquilo C₃₋₆), NHSO₂-(cicloalquilo C₃₋₆), CRˣRʸO(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F, Het, arilo o cicloalquilo C₃₋₆), CH₂O-Het, CH₂O-(cicloalquilo C₃₋₆), O(alquilo C₁₋₃ opcionalmente sustituido con uno o varios F), O(cicloalquilo C₃₋₆), O-Het, NHCO(cicloalquilo C₃₋₆, Ar o Het), cicloalquilo C₃₋₆, Het, C(O)N(H o alquilo C₁₋₃ opcionalmente sustituido con uno o varios F)(H o alquilo C₁₋₃ opcionalmente sustituido con uno o varios F) o NH(alquilo C₂₋₃ opcionalmente sustituido con uno o varios F o alquil C₁₋₃)NHCO(alquilo C₁₋₆ opcionalmente sustituido con uno o varios F); y Rˣ y Rʸ son cada uno, de modo independiente, H, alquilo C₁₋₃ (opcionalmente sustituido con hasta 3 sustituyentes seleccionados, de modo independiente, de F, OH y OCH₃), alcoxi C₁₋₃ opcionalmente sustituido con hasta 3 F o junto con el C al que están unidos, son cicloalquilo C₃₋₆.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461989615P | 2014-05-07 | 2014-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100327A1 true AR100327A1 (es) | 2016-09-28 |
Family
ID=53385685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101378A AR100327A1 (es) | 2014-05-07 | 2015-05-06 | Inhibidores de quinasa relacionados con tropomiosina |
Country Status (6)
Country | Link |
---|---|
US (1) | US9328096B2 (es) |
EP (1) | EP3140298A1 (es) |
AR (1) | AR100327A1 (es) |
TW (1) | TW201546060A (es) |
UY (1) | UY36110A (es) |
WO (1) | WO2015170218A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10160727B2 (en) | 2014-08-06 | 2018-12-25 | Shionogi & Co., Ltd. | Heterocycle and carbocycle derivatives having TrkA inhibitory activity |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
SI3319959T1 (sl) | 2015-07-06 | 2022-02-28 | Alkermes, Inc. | Hetero-halo inhibitorji histonske deacetilaze |
US10640495B2 (en) | 2015-07-07 | 2020-05-05 | Shionogi & Co., Ltd. | Heterocycle derivatives having TrkA inhibitory activity |
EP3412663B1 (en) | 2016-02-04 | 2022-09-07 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle and carbocycle derivatives having trka inhibitory activity |
MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
MA49839B1 (fr) | 2017-08-07 | 2022-05-31 | Alkermes Inc | Inhibiteurs bicycliques de la histone déacétylase |
AR122141A1 (es) * | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5556873A (en) | 1993-02-24 | 1996-09-17 | Rhone-Poulenc Inc. | Pesticidal 1-aryl-5-(substituted alkyl (thio) amido)pyrazoles |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
US6407256B1 (en) | 1999-11-03 | 2002-06-18 | Bristol Myers Squibb Co | Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors |
EP1344525A4 (en) | 2000-12-22 | 2005-05-25 | Ishihara Sangyo Kaisha | ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM |
DE60316913T2 (de) | 2002-02-12 | 2008-11-20 | Smithkline Beecham Corp. | Nicotinamide und deren verwendung als p38 inhibitoren |
WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
WO2004041789A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
DK1618092T3 (da) * | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
US7585878B2 (en) | 2003-06-12 | 2009-09-08 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア,インコーポレイテッド | サイトカイン阻害剤 |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
MXPA06013805A (es) | 2004-05-27 | 2007-02-02 | Pfizer Prod Inc | Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer. |
MX2007002584A (es) | 2004-09-02 | 2007-09-07 | Genentech Inc | Inhibidores de piridilo de senalizacion de hedgehog. |
EP1835934A4 (en) | 2004-12-23 | 2010-07-28 | Deciphera Pharmaceuticals Llc | ENZYME MODULATORS AND TREATMENTS |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
PE20080401A1 (es) | 2006-07-07 | 2008-06-23 | Boehringer Ingelheim Int | DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS |
RU2323058C1 (ru) | 2006-07-12 | 2008-04-27 | ООО Научно-внедренческий центр "Машины и оборудование для энергетики" | Способ формирования наружной резьбы на концевом участке трубной заготовки |
ES2633318T3 (es) | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met |
US8501933B2 (en) | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
WO2008071664A1 (en) | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Nicotinamide derivative used as a p38 kinase inhibitor |
WO2008071665A1 (en) | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | A nicotinamide derivative useful as p38 kinase inhibitor |
BRPI0720695A2 (pt) | 2006-12-21 | 2014-02-18 | Plexxikon Inc | Compostos e métodos para modulação de cinase, e indicações para estes |
EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
CN101678007B (zh) | 2007-04-06 | 2013-07-03 | 纽罗克里生物科学有限公司 | ***释放激素受体拮抗剂及其制药用途 |
WO2009003998A2 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
JP5572549B2 (ja) | 2007-08-13 | 2014-08-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルコキナーゼの新規な活性化剤 |
WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
AU2008319308B2 (en) | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
CN104058999A (zh) | 2008-02-29 | 2014-09-24 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009152087A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010077680A2 (en) | 2008-12-08 | 2010-07-08 | Vm Discovery Inc. | Compositions of protein receptor tyrosine kinase inhibitors |
MA32965B1 (fr) | 2009-01-12 | 2012-01-02 | Pfizer Ltd | Derives de sulfonamides |
CA2750452A1 (en) | 2009-01-30 | 2010-08-05 | Toyama Chemical Co., Ltd. | N-acyl anthranilic acid derivative or salt thereof |
CN102803203B (zh) | 2009-05-12 | 2016-05-11 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
BRPI1011247A2 (pt) | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
US20140018540A1 (en) | 2010-12-14 | 2014-01-16 | Electrophoretics Limited | Casein kinase 1delta (ck 1delta) inhibitors |
TWI523844B (zh) | 2011-01-26 | 2016-03-01 | 賽諾菲公司 | 經胺基取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途 |
US20140005245A1 (en) | 2011-02-09 | 2014-01-02 | Syngenta Participations Ag | Insecticidal compounds |
AR085318A1 (es) * | 2011-02-09 | 2013-09-25 | Syngenta Participations Ag | Derivados de triazol que tienen actividad insecticida |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
GEP20156417B (en) * | 2011-04-05 | 2015-12-25 | Pfizer Ltd | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases |
CN105130967B (zh) | 2011-05-13 | 2018-04-17 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
EP2739143B1 (en) * | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N−置換ヘテロシクリルカルボキサミド類 |
US9045478B2 (en) | 2011-12-12 | 2015-06-02 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors |
KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
JP6134376B2 (ja) | 2012-03-16 | 2017-05-24 | アクシキン ファーマシューティカルズ インコーポレーテッド | 3,5−ジアミノピラゾールキナーゼ阻害剤 |
JP6160613B2 (ja) | 2012-04-26 | 2017-07-12 | 小野薬品工業株式会社 | Trk阻害化合物 |
CA2878895A1 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
EP2912036A1 (en) * | 2012-10-04 | 2015-09-02 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
US20170197939A1 (en) | 2014-04-15 | 2017-07-13 | Pfizer Inc. | Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety |
-
2015
- 2015-04-27 WO PCT/IB2015/053060 patent/WO2015170218A1/en active Application Filing
- 2015-04-27 EP EP15728610.5A patent/EP3140298A1/en not_active Withdrawn
- 2015-05-06 UY UY0001036110A patent/UY36110A/es not_active Application Discontinuation
- 2015-05-06 US US14/705,272 patent/US9328096B2/en not_active Expired - Fee Related
- 2015-05-06 TW TW104114501A patent/TW201546060A/zh unknown
- 2015-05-06 AR ARP150101378A patent/AR100327A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201546060A (zh) | 2015-12-16 |
WO2015170218A1 (en) | 2015-11-12 |
EP3140298A1 (en) | 2017-03-15 |
US9328096B2 (en) | 2016-05-03 |
US20150322043A1 (en) | 2015-11-12 |
UY36110A (es) | 2016-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR100327A1 (es) | Inhibidores de quinasa relacionados con tropomiosina | |
AR106948A1 (es) | Agonistas del receptor de apelina y método de uso | |
AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR103199A1 (es) | N-alquilaril-5-oxiaril-octahidrociclopenta[c]pirrol moduladores alóstericos negativos de nr2b | |
AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR105929A1 (es) | Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas | |
AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
AR101798A1 (es) | Quinolinas herbicidas | |
AR101222A1 (es) | Derivados de piridona | |
AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |